比利时人群研究:高容量中心治疗的头颈癌患者生存改善
该研究基于比利时癌症登记库2009–2014年9245例头颈鳞癌患者,分析医院年诊疗量与总生存的关系。结果显示,年治疗量>20例的高容量中心患者中位生存延长1.1年(5.1年 vs 4.0年),校正混杂后每增加1例年治疗量死亡风险平均下降0.4%,超过20例后风险不再进一步下降。
要点
- 年治疗量>20例的头颈鳞癌患者中位生存较低于此容量的中心延长1.1年。
- 校正病例组合后,年治疗量每增加1例,全因死亡风险平均下降0.4%。
- 年治疗量超过20例后死亡风险无进一步下降,支持将头颈鳞癌诊疗集中于参考中心。
核心结论
- 高容量中心(>20例/年)治疗的头颈鳞癌患者生存概率显著且具有临床意义地优于低容量中心。
- 该结果支持将头颈鳞癌患者的诊疗集中于参考中心。
研究设计与样本
- 基于比利时癌症登记库的人群研究,纳入2009–2014年诊断的9245例头颈鳞癌患者。
- 登记库与其他数据库链接,获取诊断和治疗操作、生命状态及合并症信息。
- 采用Kaplan-Meier法和Ederer II法分别估计总生存率和相对生存率。
- 采用校正潜在混杂因素的Cox比例风险模型评估医院容量与诊断后总生存的关系。
主要发现
- 比利时头颈鳞癌诊疗分散于超过99个中心,其中半数中心每年治疗4例或更少。
- 年治疗量>20例的高容量中心患者中位生存为5.1年,低容量中心为4.0年,延长1.1年。
- 校正医院间病例组合后,年治疗量每增加1例,全因死亡风险平均下降0.4%。
- 年治疗量超过20例后,死亡风险不再进一步下降。
临床怎么用
- 提示应将头颈鳞癌患者转诊至年治疗量>20例的参考中心以改善生存。
- 医疗政策与区域网络建设可参考年治疗量>20例作为集中化诊疗的容量参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The study investigated the association between hospital volume and observed survival of patients with a head and neck squamous cell carcinoma (HNSCC). METHODS: Overall, 9245 patients diagnosed with HNSCC between 2009 and 2014, were identified in the population-based Belgian Cancer Registry. This database was coupled with other databases providing information on diagnostic and therapeutic procedures, vital status, and comorbidities. The overall and relative survival probabilities were estimated using the Kaplan-Meier and the Ederer II methods, respectively. The relation between hospital volume and observed survival since diagnosis was then assessed using Cox proportional hazard models adjusted for potential confounders. RESULTS: The care for patients with HNSCC in Belgium was dispersed over more than 99 centres with half of the centres treating four or less patients with HNSCC per year. Survival probabilities were significantly better for patients treated in higher volume centres (>20 patients/year): the median survival of patients treated in these centres was 1.1 year longer (5.1 versus 4.0 years) than in lower volume centres. This association was confirmed in analyses taking the case-mix between hospitals into account: the hazard to die of any cause decreased on average with 0.4% per increase of one additionally treated patient. Beyond 20 assigned patients per year, there was no further decrease in the hazard to die. CONCLUSIONS: Statistically significant and clinically relevant improved survival probabilities were obtained in patients treated in higher volume centres (>20 patients/year) compared with their peers treated in lower volume centres. This supports the recommendation to concentrate the care for patients with HNSCC in reference centres.
引用
- Leroy R, Silversmit G, Stordeur S, et al. Improved survival in patients with head and neck cancer treated in higher volume centres: A population-based study in Belgium. Eur J Cancer. 2020. PMID: 32179449. doi:10.1016/j.ejca.2020.01.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。